The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
Open accessAbstract
Activation in lectin-free interleukin 2 (IL-2) containing supernatants of peripheral blood mononuclear leukocytes (PBL) from cancer patients or normal individuals resulted in expression of cytotoxicity toward 20 of 21 natural killer (NK)-resistant fresh solid tumor cells tested. Fresh solid tumor cells were resistant to NK-mediated lysis in 10 autologous patients' PBL-tumor interactions, and from 17 normal individuals tested against 13 allogeneic fresh tumors. Culture of PBL in IL-2 for 2-3 d was required for the lymphokine activated killers (LAK) to be expressed, and lytic activity toward a variety of NK-resistant fresh and cultured tumor targets developed in parallel. Autologous IL-2 was functional in LAK activation, as well as interferon-depleted IL-2 preparations. Irradiation of responder PBL before culture in IL-2 prevented LAK development. Precursors of LAK were present in PBL depleted of adherent cells and in NK-void thoracic duct lymphocytes, suggesting that the precursor is neither a monocyte nor an NK cell. LAK effectors expressed the serologically defined T cell markers of OKT.3, Leu-1, and 4F2, but did not express the monocyte/NK marker OKM-1. Lysis of autologous fresh solid tumors by LAK from cancer patients' PBL was demonstrated in 85% of the patient-fresh tumor combinations. Our data present evidence that the LAK system is a phenomenon distinct from either NK or CTL systems that probably accounts for a large number of reported nonclassical cytotoxicities. The biological role of LAK cells is not yet known, although it is suggested that these cells may be functional in immune surveillance against human solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
A rapid method for the isolation of functional thymus‐derived murine lymphocytes
Julius, M. H., Simpson, E., & Herzenberg, L. A. (1973) · European Journal of Immunology · doi:10.1002/eji.1830031011 · Cited by 4,147
Monoclonal Antibodies Defining Distinctive Human T Cell Surface Antigens
Kung, P. C., Goldstein, G., Reinherz, E. L., & Schlossman, S. F. (1979) · Science · doi:10.1126/science.314668 · Cited by 1,453
Reinherz, E. L., Kung, P. C., Goldstein, G., & Schlossman, S. F. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.124.3.1301 · Cited by 691
Natural Killer Cells: Characteristics and Regulation of Activity
Herberman, R. B., Djeu, J. Y., Kay, H. D., Ortaldo, J. R., Riccardi, C., Bonnard, G. D., Holden, H. T., Fagnani, R., Santoni, A., & Puccetti, P. (1979) · Immunological Reviews · doi:10.1111/j.1600-065x.1979.tb00267.x · Cited by 575
Statistics: A Biomedical Introduction
Krótki, K. J., Brown, B. W., Hollander, M., & Krotki, K. J. (1980) · International Statistical Review / Revue Internationale de Statistique · doi:10.2307/1402416 · Cited by 445
Ortaldo, J. R., Sharrow, S. O., Timonen, T., & Herberman, R. B. (1981) · The Journal of Immunology · doi:10.4049/jimmunol.127.6.2401 · Cited by 389
Jondal, M., & Pross, H. F. (1975) · International Journal of Cancer · doi:10.1002/ijc.2910150409 · Cited by 313
Peter, H. H., Pavie-Fischer, J., Fridman, W. H., et al. (1975) · PubMed · Cited by 194
Monoclonal antibodies which distinguish between human NK cells and cytotoxic T lymphocytes
Zarling, J. M., & Kung, P. C. (1980) · Nature · doi:10.1038/288394a0 · Cited by 185
Cited by
Biology of Natural Killer Cells
Trinchieri, G. (1989) · Advances in Immunology · doi:10.1016/s0065-2776(08)60664-1 · Cited by 2,902
Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198704093161501 · Cited by 2,735
Self-citationRosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. T., et al. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512053132327 · Cited by 2,653
Self-citationKobayashi, M., Fitz, L., Ryan, M., Hewick, R. M., Clark, S. C., Chan, S., Loudon, R., Sherman, F., Perussia, B., & Trinchieri, G. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.3.827 · Cited by 1,953
A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes
Rosenberg, S. A., Spiess, P., & Lafreniere, R. (1986) · Science · doi:10.1126/science.3489291 · Cited by 1,880
Self-citationExercise and the immune system: regulation, integration, and adaptation
Pedersen, B. K., & Hoffman-Goetz, L. (2000) · Physiological Reviews · doi:10.1152/physrev.2000.80.3.1055 · Cited by 1,710
Shimizu, J., Yamazaki, S., & Sakaguchi, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5211 · Cited by 1,491
IL-2: The First Effective Immunotherapy for Human Cancer
Rosenberg, S. A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1490019 · Cited by 1,289
Self-citationExploring the NK cell platform for cancer immunotherapy
Myers, J. A., & Miller, J. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0426-7 · Cited by 1,276
Rosenberg, S. A. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510360033032 · Cited by 1,131
Self-citationBiology and clinical relevance of human natural killer cells
Robertson, M., & Ritz, J. (1990) · Blood · doi:10.1182/blood.v76.12.2421.2421 · Cited by 931
Fearon, E. R., Pardoll, D. M., Itaya, T., Golumbek, P., Levitsky, H. I., Simons, J. W., Karasuyama, H., Vogelstein, B., & Frost, P. (1990) · Cell · doi:10.1016/0092-8674(90)90591-2 · Cited by 916
Balkwill, F. R., & Burke, F. (1989) · Immunology Today · doi:10.1016/0167-5699(89)90085-6 · Cited by 783
Wayner, E. A., Garcia-Pardo, A., Humphries, M. J., McDonald, J. A., & Carter, W. G. (1989) · The Journal of cell biology · doi:10.1083/jcb.109.3.1321 · Cited by 783
Rosenberg, S. A., Mulé, J. J., Spiess, P. J., Reichert, C. M., & Schwarz, S. L. (1985) · The Journal of experimental medicine · doi:10.1084/jem.161.5.1169 · Cited by 745
Self-citationTreg cell-based therapies: challenges and perspectives
Raffin, C., Vo, L. T., & Bluestone, J. A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0232-6 · Cited by 720
NK cell-based cancer immunotherapy: from basic biology to clinical development
Liu, S., Galat, V., Galat4, Y., Lee, Y. K. A., Wainwright, D., & Wu, J. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01014-w · Cited by 689
Mulé, J. J., Shu, S., Schwarz, S. L., & Rosenberg, S. A. (1984) · Science · doi:10.1126/science.6332379 · Cited by 688
Self-citationPhillips, J. H., & Lanier, L. L. (1986) · The Journal of experimental medicine · doi:10.1084/jem.164.3.814 · Cited by 684
Hatakeyama, M., Tsudo, M., Minamoto, S., Kono, T., Doi, T., Miyata, T., Miyasaka, M., & Taniguchi, T. (1989) · Science · doi:10.1126/science.2785715 · Cited by 677
Adoptive-cell-transfer therapy for the treatment of patients with cancer
Dudley, M. E., & Rosenberg, S. A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1167 · Cited by 660
Self-citationBiology and regulation of IL-2: from molecular mechanisms to human therapy
Spolski, R., Li, P., & Leonard, W. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0046-y · Cited by 637
Schmidt-Wolf, I. G., Negrin, R. S., Kiem, H. P., Blume, K. G., & Weissman, I. L. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.1.139 · Cited by 614
Response of resting human peripheral blood natural killer cells to interleukin 2.
Trinchieri, G., Matsumoto-Kobayashi, M., Clark, S. C., Seehra, J., London, L., & Perussia, B. (1984) · The Journal of experimental medicine · doi:10.1084/jem.160.4.1147 · Cited by 604
The IL-2 Receptor Complex: Its Structure, Function, and Target Genes
Minami, Y., Kono, T., Miyazaki, T., & Taniguchi, T. (1993) · Annual Review of Immunology · doi:10.1146/annurev.iy.11.040193.001333 · Cited by 604
Greenberg, P. D. (1991) · Advances in Immunology · doi:10.1016/s0065-2776(08)60778-6 · Cited by 603
Biological Activity of Recombinant Human Interleukin-2 Produced in Escherichia coli
Rosenberg, S. A., Grimm, E. A., McGrogan, M., Doyle, M., Kawasaki, E., Koths, K., & Mark, D. F. (1984) · Science · doi:10.1126/science.6367046 · Cited by 595
Self-citationRole of IL-2 in cancer immunotherapy
Jiang, T., Zhou, C., & Ren, S. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1163462 · Cited by 549
Role of chemokines in the biology of natural killer cells
Robertson, M. J. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.2.173 · Cited by 516
NetPath: a public resource of curated signal transduction pathways
Kandasamy, K., Mohan, S. S., Raju, R., Keerthikumar, S., Kumar, G. S. S., Venugopal, A. K., Telikicherla, D., Navarro, J. D., Mathivanan, S., Pecquet, C., et al. (2010) · Genome Biology · doi:10.1186/gb-2010-11-1-r3 · Cited by 505
Grimm, E., Ramsey, K., Mazumder, A., Wilson, D., Djeu, J., & Rosenberg, S. (1983) · The Journal of Experimental Medicine · doi:10.1084/jem.157.3.884 · Cited by 467
Self-citationDinarello, C. A., & Mier, J. W. (1987) · New England Journal of Medicine · doi:10.1056/nejm198710083171506 · Cited by 463
Cantoni, C., Bottino, C., Vitale, M., Pessino, A., Augugliaro, R., Malaspina, A., Parolini, S., Moretta, L., Moretta, A., & Biassoni, R. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.5.787 · Cited by 452
Wayner, E. A., Carter, W. G., Piotrowicz, R. S., & Kunicki, T. J. (1988) · The Journal of cell biology · doi:10.1083/jcb.107.5.1881 · Cited by 438
Natural Killer Cells and Cancer
(2003) · Advances in Cancer Research · doi:10.1016/s0065-230x(03)90004-2 · Cited by 438
Immunotherapy of cancer in 2012
Kirkwood, J. M., Butterfield, L. H., Tarhini, A. A., Zarour, H., Kalinski, P., & Ferrone, S. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20132 · Cited by 436
Cytokines and prostaglandins in immune homeostasis and tissue destruction in periodontal disease
GEMMELL, E., MARSHALL, R. I., & SEYMOUR, G. J. (1997) · Periodontology 2000 · doi:10.1111/j.1600-0757.1997.tb00194.x · Cited by 418
Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration
Wada, Y., Nakashima, O., Kutami, R., Yamamoto, O., & Kojiro, M. (1998) · Hepatology · doi:10.1002/hep.510270214 · Cited by 405
Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance
Clarke, R., Leonessa, F., Welch, J. N., & Skaar, T. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01479-0 · Cited by 397
Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer.
Rosenberg, S. A. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.2.180 · Cited by 390
Self-citationMoretta, A., Bottino, C., Pende, D., Tripodi, G., Tambussi, G., Viale, O., Orengo, A., Barbaresi, M., Merli, A., & Ciccone, E. (1990) · The Journal of experimental medicine · doi:10.1084/jem.172.6.1589 · Cited by 385
Mazumder, A., & Rosenberg, S. A. (1984) · The Journal of experimental medicine · doi:10.1084/jem.159.2.495 · Cited by 369
Self-citationChambers, W. H., Vujanovic, N. L., DeLeo, A. B., Olszowy, M. W., Herberman, R. B., & Hiserodt, J. C. (1989) · The Journal of experimental medicine · doi:10.1084/jem.169.4.1373 · Cited by 359
Interferons and Other Cytokines
Hendrzak, J. A., & Brunda, M. J. (1997) · Cancer Therapeutics · doi:10.1007/978-1-59259-717-8_13 · Cited by 356
Clinical effects and toxicity of interleukin-2 in patients with cancer
Lotze, M. T., Matory, Y. L., Rayner, A. A., Ettinghausen, S. E., Vetto, J. T., Seipp, C. A., & Rosenberg, S. A. (1986) · Cancer · doi:10.1002/1097-0142(19861215)58:12<2764::aid-cncr2820581235>3.0.co;2-z · Cited by 355
Self-citationTUMOUR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 IN TREATMENT OF ADVANCED CANCER
Kradin, R., Lazarus, D., Dubinett, S., Gifford, J., Grove, B., Kurnick, J., Preffer, F., Pinto, C., Davidson, E., Callahan, R., et al. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91609-7 · Cited by 336
Wang, A., Lu, S.-D., & Mark, D. F. (1984) · Science · doi:10.1126/science.6427925 · Cited by 324
Itoh, K., Platsoucas, C. D., & Balch, C. M. (1988) · The Journal of experimental medicine · doi:10.1084/jem.168.4.1419 · Cited by 322
Natural killer cells and cancer
Brittenden, J., Heys, S. D., Ross, J., & Eremin, O. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960401)77:7<1226::aid-cncr2>3.0.co;2-g · Cited by 319
Hypothyroidism after Treatment with Interleukin-2 and Lymphokine-Activated Killer Cells
Atkins, M. B., Mier, J. W., Parkinson, D. R., Gould, J. A., Berkman, E. M., & Kaplan, M. M. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806163182401 · Cited by 318
Cancer Immunotherapy Using Interleukin-2 and Interleukin-2-Activated Lymphocytes
Rosenberg, S. A., & Lotze, M. T. (1986) · Annual Review of Immunology · doi:10.1146/annurev.iy.04.040186.003341 · Cited by 314
Self-citationDelivering safer immunotherapies for cancer
Milling, L., Zhang, Y., & Irvine, D. J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.011 · Cited by 305
CAR T cells: Continuation in a revolution of immunotherapy
Singh, A. K., & McGuirk, J. P. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30823-x · Cited by 303
Natural killer cell–directed therapies: moving from unexpected results to successful strategies
Terme, M., Ullrich, E., Delahaye, N. F., Chaput, N., & Zitvogel, L. (2008) · Nature Immunology · doi:10.1038/ni1580 · Cited by 289
The IL-2 cytokine family in cancer immunotherapy
Sim, G. C., & Radvanyi, L. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.018 · Cited by 278
Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders
Maskalenko, N. A., Zhigarev, D., & Campbell, K. S. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00413-7 · Cited by 256
Intratumoral LAK cell and interleukin-2 therapy of human gliomas
Barba, D., Saris, S. C., Holder, C., Rosenberg, S. A., & Oldfield, E. H. (1989) · Journal of Neurosurgery · doi:10.3171/jns.1989.70.2.0175 · Cited by 252
Self-citationCC chemokines induce the generation of killer cells from CD56+ cells
Maghazachi, A. A., Al‐Aoukaty, A., & Schall, T. J. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260207 · Cited by 163
Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy
Mesler Muul, L., Director, E. P., Hyatt, C. L., & Rosenberg, S. A. (1986) · Journal of Immunological Methods · doi:10.1016/0022-1759(86)90015-3 · Cited by 82
Self-citationAldeghi, R., Lissoni, P., Barni, S., Ardizzoia, A., Tancini, G., Piperno, A., Pozzi, M., Ricci, G., Conti, A., & Maestroni, G. J. M. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90080-9 · Cited by 44
NAGANUMA, H., SASAKI, A., SATOH, E., NAGASAKA, M., NAKANO, S., ISOE, S., TASAKA, K., & NUKUI, H. (1996) · Neurologia medico-chirurgica · doi:10.2176/nmc.36.789 · Cited by 42
Samnani, S., Sachedina, F., Gupta, M., Guo, E., & Navani, V. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.02 · Cited by 12
Metadata
- Authors
- Grimm, E. A., Mazumder, A., Zhang, H. Z., & Rosenberg, S. A.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1982-06-01
- Volume
- 155
- Issue
- 6
- Pages
- 1823-1841
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2036275492
- Cited by
- 2,204
- References
- 16
- FWCI
- 20.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.